Thrombotic and Hypercoagulability Complications of COVID-19: An Update

References

• Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402. doi:10.1002/jmv.25678
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill N, et al. World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76. doi:10.1016/j.ijsu.2020.02.034
   PubMed Web of Science ®Google Scholar
• Phan T. Novel coronavirus: from discovery to clinical diagnostics. Infect Genet Evol. 2020;79:104211. doi:10.1016/j.meegid.2020.104211
   PubMed Web of Science ®Google Scholar
• Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch Med Res. 2020;51(6):482–491. doi:10.1016/j.arcmed.2020.05.012
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. doi:10.1007/978-1-4939-2438-7_1
   PubMedGoogle Scholar
• Wong ACP, Li X, Lau SKP, Woo PCY. Global epidemiology of bat coronaviruses. Viruses. 2019;11(2):174. doi:10.3390/v11020174
   Web of Science ®Google Scholar
• V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170. doi:10.1038/s41579-020-00468-6
   PubMed Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192. doi:10.1007/s11684-020-0754-0
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Matarese A, Gambardella J, Sardu C, Santulli G. miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19. Biomedicines. 2020;8(11):462. doi:10.3390/biomedicines8110462
   PubMed Web of Science ®Google Scholar
• Sardu C, Maggi P, Messina V, et al. Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? data from centers of southern Italy. J Am Heart Assoc. 2020;9(17):e016948. doi:10.1161/JAHA.120.016948
   PubMed Web of Science ®Google Scholar
• Sanyal S. How SARS-CoV-2 (COVID-19) spreads within infected hosts—what we know so far. Emerging Topics Life Sci. 2020;4(4):383–390. doi:10.1042/ETLS20200165
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425–434. doi:10.1016/S1473-3099(20)30086-4
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(8):1621–1631. doi:10.1016/j.mayocp.2020.05.030
   PubMed Web of Science ®Google Scholar
• Tabata S, Imai K, Kawano S, et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the diamond princess cruise ship: a retrospective analysis. Lancet Infect Dis. 2020;20(9):1043–1050. doi:10.1016/S1473-3099(20)30482-5
   PubMed Web of Science ®Google Scholar
• Jenner WJ, Kanji R, Mirsadraee S, et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis. 2021;51(3):595–607. doi:10.1007/s11239-021-02394-7
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang H, Qiao R, et al. Thrombo-inflammatory features predicting mortality in patients with COVID-19: the FAD-85 score. J Int Med Res. 2020;48(9):300060520955037. doi:10.1177/0300060520955037
   Web of Science ®Google Scholar
• Harenberg J, Favaloro E. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. Clin Chem Lab Med. 2020;58(7):1029–1036. doi:10.1515/cclm-2020-0502
   PubMed Web of Science ®Google Scholar
• Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8(1):49. doi:10.1186/s40560-020-00466-z
   PubMed Web of Science ®Google Scholar
• Marcos SZ, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. Infection and thrombosis associated with COVID-19: possible role of the ABO blood group. Medicina Clínica (English Edition). 2020;155(8):340–343. doi:10.1016/j.medcle.2020.06.013
   Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
   PubMed Web of Science ®Google Scholar
• Sardu C, Gargiulo G, Esposito G, Paolisso G, Marfella R. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19(1):1–4. doi:10.1186/s12933-020-01047-y
   PubMed Web of Science ®Google Scholar
• Sardu C, D’Onofrio N, Balestrieri ML, et al. Hyperglycaemia on admission to hospital and COVID-19. Diabetologia. 2020;63(11):2486–2487. doi:10.1007/s00125-020-05216-2
   PubMed Web of Science ®Google Scholar
• Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005
   PubMed Web of Science ®Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383(2):120–128. doi:10.1056/NEJMoa2015432
   PubMed Web of Science ®Google Scholar
• Gale AJ. Continuing education course# 2: current understanding of hemostasis. Toxicol Pathol. 2011;39(1):273–280. doi:10.1177/0192623310389474
   PubMed Web of Science ®Google Scholar
• Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153–162. doi:10.1016/j.blre.2014.10.003
   PubMed Web of Science ®Google Scholar
• Bautista-Vargas M, Bonilla-Abadía F, Cañas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombolysis. 2020;50:479–483. doi:10.1007/s11239-020-02172-x
   PubMed Web of Science ®Google Scholar
• Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427
   PubMed Web of Science ®Google Scholar
• Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231(2):193–203. doi:10.1016/j.jamcollsurg.2020.05.007
   PubMed Web of Science ®Google Scholar
• Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–e82. doi:10.1016/S2352-3026(20)30216-7
   PubMed Web of Science ®Google Scholar
• Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45. doi:10.1038/nri3345
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374. doi:10.1038/s41577-020-0311-8
   PubMed Web of Science ®Google Scholar
• Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. New Engl J Med. 2020;383(6):590–592. doi:10.1056/NEJMc2011400
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374. doi:10.1007/s11427-020-1643-8
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17–41. doi:10.1002/JLB.3COVR0520-272R
   PubMed Web of Science ®Google Scholar
• Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2020;51:1–17.
   Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. doi:10.1016/j.trsl.2020.04.007
   PubMed Web of Science ®Google Scholar
• Fletcher-Sandersjöö A, Bellander B-M. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res. 2020;194:36–41. doi:10.1016/j.thromres.2020.06.027
   PubMed Web of Science ®Google Scholar
• Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627–1738.
   PubMed Web of Science ®Google Scholar
• Celi A, Cianchetti S, Dell’Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther. 2010;8(12):1723–1729. doi:10.1586/erc.10.161
   PubMedGoogle Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. doi:10.1001/jamacardio.2020.1017
   PubMed Web of Science ®Google Scholar
• Becker RC. COVID-19 update: covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67. doi:10.1007/s11239-020-02134-3.
   Google Scholar
• Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection a scoping review. Thromb Res. 2020;192:152–160. doi:10.1016/j.thromres.2020.05.039
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng X, Zhang D, et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020;142(2):114–128. doi:10.1161/circulationaha.120.046702
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.017
   PubMed Web of Science ®Google Scholar
• Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi:10.1016/S2352-3026(20)30145-9
   PubMed Web of Science ®Google Scholar
• Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thrombosis Haemostasis. 2020;18(5):1023–1026. doi:10.1111/jth.14810
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):15–31. doi:10.1007/s11239-015-1314-3
   PubMed Web of Science ®Google Scholar
• Kim SY, Jin W, Sood A, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 2020;181:104873. doi:10.1016/j.antiviral.2020.104873
   Web of Science ®Google Scholar
• Thachil J. The versatile heparin in COVID-19. J Thrombosis Haemostasis. 2020;18(5):1020–1022. doi:10.1111/jth.14821
   PubMed Web of Science ®Google Scholar
• White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020;50(2):287–291. doi:10.1007/s11239-020-02145-0
   PubMed Web of Science ®Google Scholar
• Ortega‐Paz L, Capodanno D, Montalescot G, Angiolillo Dominick J. Coronavirus disease 2019–associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10(3):e019650. doi:10.1161/JAHA.120.019650
   Web of Science ®Google Scholar
• Chen S, Zhang D, Zheng T, Yu Y, Jiang J. DVT incidence and risk factors in critically ill patients with COVID-19. J Thromb Thrombolysis. 2021;51(1):33–39. doi:10.1007/s11239-020-02181-w
   PubMed Web of Science ®Google Scholar
• Shah A, Donovan K, McHugh A, et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Critical Care. 2020;24(1):1–10. doi:10.1186/s13054-020-03260-3
   Web of Science ®Google Scholar
• Gibson CJ, Alqunaibit D, Smith KE, et al. Probative value of the d-dimer assay for diagnosis of deep venous thrombosis in the coronavirus disease 2019 syndrome. Crit Care Med. 2020;48(12):e1322–e1326. doi:10.1097/ccm.0000000000004614
   Web of Science ®Google Scholar
• Monfardini L, Morassi M, Botti P, et al. Pulmonary thromboembolism in hospitalised COVID-19 patients at moderate to high risk by Wells score: a report from Lombardy, Italy. Br J Radiol. 2020;93(1113):20200407. doi:10.1259/bjr.20200407
   Web of Science ®Google Scholar
• Avruscio G, Camporese G, Campello E, et al. COVID‐19 and venous thromboembolism in intensive care or medical ward. Clin Transl Sci. 2020;13(6):1108–1114. doi:10.1111/cts.12907
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500. doi:10.1182/blood.2020006520
   PubMed Web of Science ®Google Scholar
• Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192:23–26. doi:10.1016/j.thromres.2020.05.018
   PubMed Web of Science ®Google Scholar
• Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–2072. doi:10.1016/j.jacc.2020.08.070
   PubMed Web of Science ®Google Scholar
• Brosnahan SB, Jonkman AH, Kugler MC, Munger JS, Kaufman DA. COVID-19 and respiratory system disorders: current knowledge, future clinical and translational research questions. Arterioscler Thromb Vasc Biol. 2020;40(11):2586–2597. doi:10.1161/ATVBAHA.120.314515
   PubMed Web of Science ®Google Scholar